探索与脑膜瘤中CDKN2A/B状态相关的人口,临床,外科和成像特征
Hanan Abofani1, Ofir Ben-Moyal1, Zvi R Cohen2
1Department of Neurosurgery, Neurosurgical Oncology and Radiosurgery Unit, Sheba Medical Center, Ramat Gan, Israel.
World neurosurgery
|December 4, 2025
概括
在脑膜瘤中预测CDKN2A/B删除具有挑战性. 人口,临床和成像特征无法可靠地预测删除状态,支持通用测试以获得准确的世卫组织分类.
科学领域:
- 神经瘤学神经瘤学
- 分子病理学分子病理学
- 神经外科 神经外科
背景情况:
- 脑膜瘤是常见的原发性脑瘤,具有侵略性的亚型,带来了重大的临床挑战.
- 2021年世界卫生组织分类将CDKN2A/B同卵性缺失指定为3级脑膜瘤的标准,强调其预后的重要性.
研究的目的:
- 调查人口统计学,临床或放射学特征是否可以预测内脑膜瘤中CDKN2A/B删除状态.
- 评估标准临床和成像参数在指导脑膜瘤分级的CDKN2A/B测试中的有用性.
主要方法:
- 追溯分析77名接受内脑膜瘤手术切除的患者.
- 评估手术前的MRI特征,包括瘤体积,,增强,扩散限制和CSF裂保存.
- 通过FISH确定CDKN2A/B删除状态,并使用统计测试对删除和未删除组进行比较.
主要成果:
- 在77名患者中,9名 (11.6%) 患有CDKN2A/B删除. 在删除阳性和消极组之间,在年龄,性别,瘤体积或成像特征方面没有发现显著差异.
- 组织学等级和Ki-67指数在不同组中是相似的;几个删除阳性病例是世卫组织等级I或II.
- 人口,临床和放射学特征无法可靠地预测CDKN2A/B删除状态.
结论:
- 临床和成像特征是CDKN2A/B删除在脑膜瘤的不充分预测因素.
- 在形态分级和分子状态 (CDKN2A/B删除) 之间存在差异,影响了精确的瘤分类.
- 建议进行通用CDKN2A/B测试,以准确对脑膜瘤进行世卫组织分类和风险分层.
相关概念视频
02:15M-Cdk Drives Transition Into Mitosis
6.2K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.2K
02:34Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K